A Study to Better Understand the Role of the Hormones Glucagon and Insulin in the Progression of Diabetes


About this study

The purpose of this study is to determine the longitudinal effect of diabetes-associated variation in TCF7L2 on a-cell function and the contribution of a-cell function to longitudinal glucose tolerance and EGP in non-diabetic subjects.  

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • We will recruit a new cohort of nondiabetic subjects in whom genotype at rs7903146 is known.   
  • Individuals genotyped will be randomly selected from the Biobank cohort encompassing the age span of 25-70 years.  
  • Have no history of diabetes  
  • Reside within a 100 mile radius of Mayo Clinic, Rochester, MN 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

Contact information:

Paula Giesler R.N.



More information


Publications are currently not available

Mayo Clinic Footer